Asensus Surgical Inc. (ASXC): Price and Financial Metrics
ASXC Price/Volume Stats
| Current price | $0.29 | 52-week high | $1.18 |
| Prev. close | $0.26 | 52-week low | $0.20 |
| Day low | $0.26 | Volume | 2,116,100 |
| Day high | $0.29 | Avg. volume | 1,185,685 |
| 50-day MA | $0.29 | Dividend yield | N/A |
| 200-day MA | $0.37 | Market Cap | 75.70M |
ASXC Stock Price Chart Interactive Chart >
ASXC Stock Summary
- For ASXC, its debt to operating expenses ratio is greater than that reported by just 12.34% of US equities we're observing.
- ASXC's price/sales ratio is 14.94; that's higher than the P/S ratio of 92.7% of US stocks.
- In terms of volatility of its share price, ASXC is more volatile than 90.67% of stocks we're observing.
- Stocks that are quantitatively similar to ASXC, based on their financial statements, market capitalization, and price volatility, are ONVO, LGVN, AKTS, FCEL, and WATT.
- Visit ASXC's SEC page to see the company's official filings. To visit the company's web site, go to www.transenterix.com.
ASXC Valuation Summary
- In comparison to the median Healthcare stock, ASXC's price/earnings ratio is 103.77% lower, now standing at -1.1.
- ASXC's price/sales ratio has moved up 14.2 over the prior 243 months.
Below are key valuation metrics over time for ASXC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ASXC | 2023-12-29 | 15.0 | 1.8 | -1.1 | -0.8 |
| ASXC | 2023-12-28 | 16.0 | 1.9 | -1.1 | -0.9 |
| ASXC | 2023-12-27 | 16.7 | 2.0 | -1.2 | -1.0 |
| ASXC | 2023-12-26 | 16.8 | 2.0 | -1.2 | -1.0 |
| ASXC | 2023-12-22 | 15.4 | 1.8 | -1.1 | -0.9 |
| ASXC | 2023-12-21 | 14.6 | 1.7 | -1.0 | -0.8 |
ASXC Growth Metrics
- Its 2 year revenue growth rate is now at 3.81%.
- Its 5 year cash and equivalents growth rate is now at -3.3%.
- The 4 year net cashflow from operations growth rate now stands at -20.01%.
The table below shows ASXC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 7.099 | -58.056 | -73.552 |
| 2022-06-30 | 7.107 | -52.404 | -70.697 |
| 2022-03-31 | 7.215 | -46.365 | -64.25 |
| 2021-12-31 | 8.232 | -40.659 | -62.462 |
| 2021-09-30 | 6.863 | -40.252 | -60.372 |
| 2021-06-30 | 5.106 | -40.024 | -59.385 |
ASXC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ASXC has a Quality Grade of D, ranking ahead of 5.14% of graded US stocks.
- ASXC's asset turnover comes in at 0.038 -- ranking 163rd of 186 Medical Equipment stocks.
- ARAY, ATRC, and INGN are the stocks whose asset turnover ratios are most correlated with ASXC.
The table below shows ASXC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.038 | -0.370 | -1.090 |
| 2021-06-30 | 0.034 | -0.464 | -1.879 |
| 2021-03-31 | 0.041 | -0.404 | -2.039 |
| 2020-12-31 | 0.040 | -0.627 | -2.331 |
| 2020-09-30 | 0.035 | -4.608 | -2.502 |
| 2020-06-30 | 0.048 | -3.407 | -4.864 |
Asensus Surgical Inc. (ASXC) Company Bio
Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, economic shortcomings in surgery. The Senhance Surgical System features as the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling in 2006 and is headquartered in Morrisville, NC.
Latest ASXC News From Around the Web
Below are the latest news stories about ASENSUS SURGICAL INC that investors may wish to consider to help them evaluate ASXC as an investment opportunity.
Asensus Announces Sale of Senhance Robotic System in RomaniaSenhance® System to be placed at a pediatric hospital in Timisoara, Romania Senhance Surgical System The Senhance Surgical System was developed to address the challenges of pediatric surgery while preserving the benefits of minimally invasive surgery. RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, announced the sale of a Senhance® Surgical Syst |
3 Stocks at the Forefront of Medical RoboticsEvery now and then, speculation – within carefully defined limits – may be appropriate, which brings us to the case for medical robotics stocks to buy. |
Senhance Robotic System Sold by Asensus SurgicalSenhance® System to be placed at a hospital in the Commonwealth of Independent States Senhance Surgical System The Senhance Surgical System is the only commercially available robotic surgery system with haptic feedback, a differentiating feature for surgeons. RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company digitizing the interface between the surgeon and patient, announced that a Senhance® Surgical System has |
Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the third quarter 2023. Recent Highlights 17% growth in surgical procedures, with over 2,700 procedures performed globally year to date at September 30, 2023Two Senhance Surgical programs |
Asensus Surgical Announces Sale of Senhance Robotic SystemSenhance® System to be placed at a pediatric hospital in the Commonwealth of Independent States Senhance Robotic System A Senhance Surgical System will be placed in a pediatric hospital in the Commonwealth of Independent States (CIS) region. RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company digitizing the interface between the surgeon and the patient, announced that a Senhance® Surgical System was sold to the Co |
ASXC Price Returns
| 1-mo | -17.40% |
| 3-mo | 38.10% |
| 6-mo | -14.73% |
| 1-year | -57.82% |
| 3-year | -93.11% |
| 5-year | -99.12% |
| YTD | -9.06% |
| 2023 | -8.12% |
| 2022 | -68.73% |
| 2021 | 77.60% |
| 2020 | -57.48% |
| 2019 | -95.00% |
Loading social stream, please wait...